GAFA
LGND icon

Garton & Associates Financial Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Garton & Associates Financial Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25
Closed -$4.73K – 433
2025
Q4 		$4.73K Buy
+25
New +$4.8K ﹤0.01% 1004

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Garton & Associates Financial Advisors's LGND Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 25 shares — an estimated $4.73K sold.

Garton & Associates Financial Advisors first reported a position in LGND in Q4 2025 and held it in 1 quarter. The position peaked at $4.73K in Q4 2025. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Garton & Associates Financial Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Garton & Associates Financial Advisors sold 25 Ligand Pharmaceuticals shares in Q1 2026, an estimated $4.73K.
  • Garton & Associates Financial Advisors first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Garton & Associates Financial Advisors's Ligand Pharmaceuticals position peaked at $4.73K in Q4 2025.
  • 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.